Osimertinib versus gefitinib followed by osimertinib in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE trial

被引：0

作者：

Masip, J. Remon ^{[1
]}

Besse, B. ^{[1
]}

Aix, S. Ponce ^{[2
]}

Perez, A. Callejo ^{[3
]}

Al-Rabi, K. ^{[4
]}

Caro, R. Bernabe ^{[5
]}

Greillier, L. ^{[6
]}

Tarruella, M. Majem ^{[7
]}

Aransay, N. Reguart ^{[8
]}

Monnet, I. ^{[9
]}

Cousin, S. ^{[10
]}

Lopez, P. Garrido ^{[11
]}

Robinet, G. ^{[12
]}

Campelo, R. Garciaprime ^{[13
]}

Flandin, A-C. Madroszyk ^{[14
]}

Mazieres, J. ^{[15
]}

Curcio, H. ^{[16
]}

Pretzenbacher, Y. ^{[17
]}

Dingemans, A-M. C. ^{[18
]}

Dziadziuszko, R. ^{[19
]}

机构：

[1] Inst Gustave Roussy, Oncol Dept, Villejuif, France

[2] Hosp Univ 12 Octubre, Med Oncol Dept, Madrid, Spain

[3] Vall dHebron Univ Hosp, Oncol Dept, Barcelona, Spain

[4] KHCC King Hussein Canc Ctr, Med Oncol & Hematol Dept, Amman, Jordan

[5] Hosp Univ Virgen Rocio, Seville, Spain

[6] Hop St Marguerite Assistance Publ Hop Marseille, Multidisciplinary Oncol & Therapeut Innovat, Marseille, France

[7] Hosp Santa Creu & Sant Pau, Barcelona, Spain

[8] Hosp Clin Barcelona, Med Oncol Dept, Barcelona, Spain

[9] Chi Creteil, Creteil, France

[10] Inst Bergonie, Early Phase Trials, Bordeaux, France

[11] Hosp Univ Ramon & Cajal, Med Oncol Dept, Madrid, Spain

[12] CHRU Brest Hop Morvan, Brest, France

[13] CHUAC Complexo Hosp Univ A Coruna, La Coruna, Spain

[14] IPC Inst Paoli Calmettes, Marseille, France

[15] Ctr Hosp Univ Toulouse, Thorac Oncol Dept, Hop Larrey, Toulouse, France

[16] Ctr Francois Baclesse, Oncol Dept, Caen, France

[17] EORTC AISBL IVZW European Org Res & Treatment Can, Stat, Brussels, Belgium

[18] Erasmus MC Univ, Pulmonol Dept, Med Ctr, Rotterdam, Netherlands

[19] Med Univ Gdansk, Oncol & Radiotherapy Dept, Gdansk, Poland

来源：

JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S35 / S35

页数：1

共 50 条

[21] Local control of brain metastases with osimertinib alone in patients with EGFR-mutant non-small cell lung cancer
Hui, Caressa
Qu, Vera
Wang, Jen-Yeu
von Eyben, Rie
Chang, Yu-Cheng
Chiang, Po-Lin
Liang, Chih-Hung
Lu, Jen-Tang
Li, Gordon
Hayden-Gephart, Melanie
Wakelee, Heather
Neal, Joel
Ramchandran, Kavitha
Das, Millie
Nagpal, Seema
Soltys, Scott
Myall, Nathaniel
Pollom, Erqi
JOURNAL OF NEURO-ONCOLOGY, 2022, 160 (01) : 233 - 240
[22] Local Control of Brain Metastases with Osimertinib Alone in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
Hui, C.
Qu, V.
Wang, J. Y.
Von Eyben, R.
Chang, Y. C.
Chiang, P. L.
Liang, C. H.
Lin, J. Y.
Lu, J. T.
Li, G.
Hayden, M.
Myall, N.
Soltys, S. G.
Pollom, E.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E54 - E55
[23] Prognosticators of osimertinib treatment outcomes in patients with EGFR-mutant non-small cell lung cancer and leptomeningeal metastasis
Chiang, Chi-Lu
Ho, Hsiang-Ling
Yeh, Yi-Chen
Lee, Cheng-Chia
Huang, Hsu-Ching
Shen, Chia-, I
Luo, Yung-Hung
Chen, Yuh-Min
Chiu, Chao-Hua
Chou, Teh-Ying
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (01) : 5 - 14
[24] Impact of sequential therapy with osimertinib on the overall survival in patients with EGFR-mutant non-small cell lung cancer
Inomata, Minehiko
Matsumoto, Masahiro
Mizushima, Isami
Hayashi, Kana
Seto, Zenta
Tokui, Kotaro
Taka, Chihiro
Okazawa, Seisuke
Kambara, Kenta
Imanishi, Shingo
Miwa, Toshiro
Hayashi, Ryuji
Matsui, Shoko
Tobe, Kazuyuki
EGYPTIAN JOURNAL OF BRONCHOLOGY, 2022, 16 (01)
[25] Prognosticators of osimertinib treatment outcomes in patients with EGFR-mutant non-small cell lung cancer and leptomeningeal metastasis
Chi-Lu Chiang
Hsiang-Ling Ho
Yi-Chen Yeh
Cheng-Chia Lee
Hsu-Ching Huang
Chia-I Shen
Yung-Hung Luo
Yuh-Min Chen
Chao-Hua Chiu
Teh-Ying Chou
Journal of Cancer Research and Clinical Oncology, 2023, 149 : 5 - 14
[26] Impact of sequential therapy with osimertinib on the overall survival in patients with EGFR-mutant non-small cell lung cancer
Minehiko Inomata
Masahiro Matsumoto
Isami Mizushima
Kana Hayashi
Zenta Seto
Kotaro Tokui
Chihiro Taka
Seisuke Okazawa
Kenta Kambara
Shingo Imanishi
Toshiro Miwa
Ryuji Hayashi
Shoko Matsui
Kazuyuki Tobe
The Egyptian Journal of Bronchology, 2022, 16
[27] Osimertinib beyond Progression in Patients with EGFR Mutated Non-small Cell Lung Cancer (NSCLC) Receiving Frontline Osimertinib
Benyounes, A.
Cohen, A.
Rossi, S. Diamond
Cannon, T.
Yacur, M.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S657 - S657
[28] Acquired BRAF gene fusions in Osimertinib resistant EGFR-mutant non-small cell lung cancer
Rosell, Rafael
Gonzalez-Cao, Maria
Codony-Servat, Jordi
Molina-Vila, Miguel Angel
Mayo de las Casas, Clara
Ito, Masaoki
TRANSLATIONAL CANCER RESEARCH, 2023, 12 (03) : 456 - 460
[29] MERTK activation drives osimertinib resistance in EGFR-mutant non small cell lung cancer
Yan, Dan
Huelse, Justus M.
Kireev, Dmitri
Tan, Zikang
Chen, Luxiao
Goyal, Subir
Wang, Xiaodong
Frye, Stephen, V
Behera, Madhusmita
Schneider, Frank
Ramalingam, Suresh S.
Owonikoko, Taofeek
Earp, H. Shelton
DeRyckere, Deborah
Graham, Douglas K.
JOURNAL OF CLINICAL INVESTIGATION, 2022, 132 (15):
[30] Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer
Lemmon, Christopher A.
Zabor, Emily C.
Pennell, Nathan A.
ONCOLOGIST, 2022, 27 (05): : 407 - 413

← 1 2 3 4 5 →